Markets

IMNN|EPS -$6.83|Net Loss $14.5M IMUNON is a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies. The company’s lead clinical program, IMNN-001, is currently advancing through a pivotal Phase 3 trial for the localized treatment of newly diagnosed advanced ovarian cancer. For the year ended December 31, 2025, IMUNON recorded $0 in revenue. The company’s earnings […]

BKYI|EPS -$0.19|Rev $1.2M|Net Loss $1.7M BIO-key International, Inc. reported a Q4 2025 loss per share of -$0.19, marking a substantial improvement from the -$0.46 loss posted in the same quarter last year as the identity and access management solutions provider navigates a challenging revenue environment. The company’s loss per share narrowed 58.7% year-over-year despite ongoing

PRPL|EPS -$0.02|Rev $140.7M|Net Loss $3.2M Purple Innovation, Inc. (PRPL) posted Q4 2025 adjusted EPS of -$0.02. Revenue totaled $140.7M for the quarter. Revenue was up 9.1% year-over-year. Purple Innovation, Inc. is a Furnishings, Fixtures & Appliances company. Adjusted EBITDA was $9M for the quarter. Bottom line showed a net loss of $3.2M. Looking ahead, the

ALLR|EPS -$0.78|Rev $320,000|Net Loss $11.2M Allarity Therapeutics, Inc. reported a loss per share of $0.78 for the full year of 2025, as the clinical-stage precision medicine company continued advancing its pipeline of novel anti-cancer therapeutics. The company posted a net loss of $11.2M for the year while generating revenue of $320,000. The Allarity results reflect

MKC|EPS $0.66|Rev $1.87B|Net Income $1.02B Guidance adjusted $3.05 – $3.13|Stock $49.47  Solid beat. McCormick & Company, Incorporated (NYSE:MKC) delivered Q1 2026 adjusted EPS of $0.66, clearing expectations as the spice and seasonings giant posted revenue of $1.87B, up 16.7% from $1.61B in the year-ago quarter. The impressive top-line expansion demonstrates momentum across the company’s portfolio,

JILL|EPS -$0.02 vs $0.60 est (-103.3%)|Rev $138.4M|Net Loss $3.5M Stock $12.19  Significant Miss. J.Jill, Inc. (NYSE:JILL) delivered a disappointing fourth quarter, reporting an adjusted loss of $0.02 per share against Wall Street’s consensus estimate of $0.60 earnings per share, representing a miss by 103.3%. The apparel retailer generated $138.4M in revenue for the quarter, down

OSTX|EPS -$0.98|Net Loss $28.8M OS Therapies Incorporated posted a loss per share of $0.98 for the full year of 2025, as the clinical stage biopharmaceutical company continues to invest heavily in developing treatments for osteosarcoma and other solid tumors. The company reported a net loss of $28.8M for the year. The results reflect the capital-intensive

PVLA|EPS -$3.71|Net Loss $41.7M Palvella Therapeutics, Inc. reported a narrower loss for the full year of 2025, reflecting improved financial performance as the clinical-stage biopharmaceutical company advances its pipeline of therapies for serious and rare genetic skin diseases. The Wayne, Pennsylvania-based firm posted a loss per share of $3.71 for the year, a marked improvement